Skip To Main Content
Chiara Catania on Muck Rack

Chiara Catania

As seen in: MDPI, JAMA Oncology, Cell Press, The Lancet, Dialnet - Universidad de La Rioja, Lung Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Chiara

Contact Chiara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

No Other Land (2024), by Hamdan Ballal, Yuval Abraham, Basel Adra, Rachel Szor

|
By Chiara Catania
| Dialnet - Universidad de La Rioja
Ayuda Buscar en la ayuda Buscar en la ayuda No Other Land (2024), by Hamdan Ballal, Yuval Abraham, Basel Adra, Rachel Szor Catania, Chiara [1] [1] University of Turin Localización: Journal of Artistic Creation and Literary Research, ISSN-e 2340-650X, Vol. 13, Nº. 1, 2025 (Ejemplar dedicado a: Journal of Artistic Creation and Literary Research), págs. 141-144 Idioma: inglés Enlaces Texto completo
Open in Who Shared Issue with article?

Sex hormones, the anticancer immune response, and therapeutic opportunities

|
By Fabio Conforti, Laura Pala, Diletta Di Mitri, Chiara Catania, Emilia Cocorocchio, Daniele Laszlo, Giovanni L Ceresoli, Marzia Locatelli, Flaminia Facella, Tommaso De Pas, Benedetta Rambaldi, Alessandro Rambaldi, Giuseppe Viale, Vincenzo Bagnardi, Giuseppe Giaccone, Alberto Mantovani
| Cell Press Verified
Keywords sex-specific differences sex hormones manipulation tumor immune microenvironment androgen and estrogen receptros cancer immunotherapy Introduction Immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized the therapeutic landscape for patients with several solid tumors.1,2 Nevertheless, many patients fail to respond to these treatments, underscoring the pressing clinical need to discover new therapeutic strategies to overcome resistance mechanisms.1,2 Recent reports...
Open in Who Shared Issue with article?

First Report of Pembrolizumab Activity in KIT-Mutated Thymic Carcinoma

|
By Giuseppe Giaccone, Chiara Catania, Fabio Conforti, Laura Pala
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?
See all 7 articles